Cempra Pharmaceuticals
Cempra develops novel, well-differentiated antibiotics to meet critical medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
Learn More
News and Events
TakstaTM (fusidic acid) Demonstrates Activity against MRSA Isolated from Cystic Fibrosis Patients
- Cempra Pharmaceuticals will be presenting data demonstrating Taksta's activity against Methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from cystic fibrosis (CF) patients and demonstrating solithromycin's anti-inflammatory activity in a human lung epithelial....
Additional Data on the Mechanistic Characterization of Adverse Events of Voriconazole and Telithromycin to be Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA)
- Additional data will be presented on the mechanistic characterization of adverse events reported with the azole antifungal, voriconazole, and the ketolide antibiotic, telithromycin, at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). The....
View All [+]
Quick Links